Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of Armata Pharmaceuticals (NYSEAMERICAN:ARMP) to a hold rating in a report published on Monday,Zacks.com reports.

Separately, HC Wainwright boosted their price objective on Armata Pharmaceuticals from $9.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, February 23rd. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $15.00.

Armata Pharmaceuticals Stock Performance

Shares of Armata Pharmaceuticals stock opened at $8.46 on Monday. Armata Pharmaceuticals has a 52-week low of $1.74 and a 52-week high of $16.34. The stock’s 50-day simple moving average is $10.25 and its 200 day simple moving average is $8.20. The stock has a market capitalization of $310.57 million, a P/E ratio of -1.09 and a beta of 1.31.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($3.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($2.78). The company had revenue of $0.79 million during the quarter, compared to analyst estimates of $0.74 million. Equities research analysts forecast that Armata Pharmaceuticals will post -1.88 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE grew its holdings in Armata Pharmaceuticals by 233.2% during the 1st quarter. Bank of America Corp DE now owns 11,714 shares of the company’s stock valued at $120,000 after buying an additional 8,198 shares in the last quarter. Sei Investments Co. purchased a new position in Armata Pharmaceuticals during the 1st quarter valued at about $760,000. Madison Asset Management LLC purchased a new position in Armata Pharmaceuticals during the 1st quarter valued at about $21,583,000. Millennium Management LLC purchased a new position in Armata Pharmaceuticals during the 4th quarter valued at about $164,000. Finally, 683 Capital Management LLC purchased a new position in Armata Pharmaceuticals during the 4th quarter valued at about $878,000. Hedge funds and other institutional investors own 3.57% of the company’s stock.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.